Product
IBI311
4 clinical trials
3 indications
Indication
Graves' DiseaseIndication
HealthyIndication
Thyroid Eye DiseaseClinical trial
A Multicenter, Randomized, Double-masked, Placebo-controlled Phase II/III Study Evaluating the Efficacy and Safety of IBI311 in Subjects With Active Thyroid Eye DiseaseStatus: Completed, Estimated PCD: 2023-12-20
Clinical trial
A Dose Escalation Phase I Clinical Study to Evaluate the Tolerability and Safety of a Single Intravenous Injection IBI311 in Healthy VolunteersStatus: Completed, Estimated PCD: 2022-11-23
Clinical trial
A Multicenter, Open-label Extension Study Evaluating the Efficacy and Safety of IBI311 in Subjects With Thyroid Eye DiseaseStatus: Recruiting, Estimated PCD: 2025-02-15
Clinical trial
An Exploratory Study of the Efficacy and Safety of IBI311, a Modified Anti-IGF-1R Antibody, in Patients With Steroid-resistant, Thyroid Associated OphthalmopathyStatus: Active (not recruiting), Estimated PCD: 2025-06-01